NANOBIOTIX to Present at the H.C. Wainwright Global Life Sciences Conference
03 Marzo 2021 - 10:15PM
Business Wire
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO ––
NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage
biotechnology company pioneering physics-based approaches to expand
treatment possibilities for patients with cancer, today announced
that Laurent Levy, Chief Executive Officer, will speak during a
fireside chat at the H.C. Wainwright Global Life Science
Conference, being held virtually on March 9-10, 2021.
Event Details:
- Title: H.C. Wainwright Global Life Sciences Conference
- Date: Tuesday, March 9, 2021 to Wednesday, March 10, 2021
- Time: Available on Demand
- Registration: https://hcwevents.com/globalconference/
Members of the Nanobiotix management team will also be available
to participate in virtual one-on-one meetings with investors who
are registered to attend the conference. The Company’s corporate
presentation can be downloaded here.
About NBTXR3
NBTXR3 is a first-in-class radioenhancer composed of sterile,
functionalized, crystalline hafnium oxide nanoparticles. The
product candidate is designed to increase the radiotherapy energy
deposit inside tumor cells through the nanoparticles’ high atomic
number core packaged in the space for interaction with ionizing
radiation, and subsequently increase of tumor cell death when
compared to radiotherapy alone—without adding toxicity to adjacent
healthy tissues. NBTXR3 requires a single, intratumoral
administration before the first radiotherapy treatment session, and
has the ability to fit into current worldwide standards of
radiation care. The primary physical mechanism of action of NBTXR3
activated by radiotherapy could be universal, making it potentially
applicable across any solid tumor indication where radiotherapy is
a part of standard of care including head and neck, lung, prostate,
liver, colorectal, and esophageal cancers. The biological secondary
mechanism of action of NBTXR3 activated by radiotherapy has been
shown in preclinical studies to prime adaptive immune response,
which would potentially bring a new dimension to cancer
immunotherapies.
About NANOBIOTIX: www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a clinical-stage
biotechnology company pioneering physics-based approaches to expand
treatment possibilities for patients with cancer and other major
diseases.
The Nanobiotix philosophy is rooted in bringing highly
effective, generalized solutions to address unmet medical needs and
challenges.
The Company’s first-in-class, proprietary lead technology,
NBTXR3, is being evaluated in an expansive global development
program both as a single agent activated by radiotherapy and in
combination with other anti-cancer therapies including chemotherapy
and immune checkpoint inhibitors.
Nanobiotix is listed on the regulated market of Euronext in
Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP)
and on the Nasdaq Global Select Market (Nasdaq: NBTX). The
Company’s headquarters are in Paris, France, with a U.S. affiliate
in Cambridge, MA, and European affiliates in France, Spain and
Germany
Disclaimer
This press release contains certain “forward-looking” statements
within the meaning of applicable securities laws, including the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by words such as “at this time,”
“anticipate,” “believe,” “expect,” “intend,” “on track,” “plan,”
“scheduled,” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management, include statements
about the timing and progress of clinical trials, the timing of our
presentation of data, the results of our preclinical studies and
their potential implications. Such forward-looking statements are
made in light of information currently available to us and based on
assumptions that Nanobiotix considers to be reasonable. However,
these forward-looking statements are subject to numerous risks and
uncertainties, including with respect to the challenges associated
with developing NBTXR3 in the Asia-Pacific region or identifying a
suitable collaboration partner for such development activities, the
risk that subsequent studies and clinical trials may not generate
favorable data notwithstanding positive preclinical result and the
risks associated with the evolving nature of the duration and
severity of the COVID-19 pandemic and governmental and regulatory
measures implemented in response to it. Furthermore, many other
important factors, including those described in our prospectus
filed with the U.S. Securities and Exchange Commission on December
11, 2020 under the caption “Risk Factors” and those set forth in
the universal registration document of Nanobiotix registered with
the French Financial Markets Authority (Autorité des Marchés
Financiers) under number R.20-010 on May 12, 2020 (a copy of which
is available on www.nanobiotix.com), as well as other known and
unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210303005874/en/
Nanobiotix
Communications Department Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com
Investor Relations Department Kate McNeil SVP, Investor
Relations +1 (609) 678-7388 investors@nanobiotix.com
Media Relations
France – Ulysse Communication Pierre-Louis Germain + 33
(0) 6 64 79 97 51 plgermain@ulysse-communication.com
US – Porter Novelli Stefanie Tuck +1 (917) 390-1394
Stefanie.tuck@porternovelli.com
Grafico Azioni Nanobiotix (EU:NANO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Nanobiotix (EU:NANO)
Storico
Da Apr 2023 a Apr 2024